Navigation Links
Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks
Date:8/26/2014

Toronto, Canada (PRWEB) August 26, 2014

Historically, drug development has faced a number of challenges and the list continues to grow – high attrition rate, low productivity, patent expiry, rising costs of research and development, high regulatory hurdles and increasing concern about adverse side effects. It has also become clear that the traditional business model of pharmaceutical companies is no longer sustainable. Pharmaceutical companies are now seeking to find better ways to reduce operational costs and increase output of new drugs through innovation within research and development.

Drug research and development is a dynamic process, requiring integration of activities across a number of preclinical scientific disciplines for successful progression of therapeutic candidates. The presentation will review the critical challenges in pharmaceutical R&D and highlight how innovative approaches can help to overcome these hurdles. Dr. Yan will also share some cases to illustrate how Covance has helped its partners reach their unique milestones by applying a seamless and strategic approach.

This webinar is part of a series presented by Covance titled “Insights on Improving Global Drug Development from Bench to Commercialization.” For more information about the series or to register for this webinar visit: Transitioning from Bench into Clinical Phase.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Oklahoma State Medicaid Adopts Drug Price Benchmark, PAC
2. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
3. Xinmeiya Technology Releases Their 5C7-195 Benchtop Thermoelectric Controller
4. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
5. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
6. BioInformatics, LLC Deploys RateMyProduct™ to Rate Benchtop Real-time PCR Machines
7. Global Catalysts Industry 2013-2018: Trend, Profit, and Forecast Analysis - Benchmark the Worlds Top 5 Drug Companies
8. InspireMD To Participate In Benchmark Investor Conference On May 30th
9. HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013
10. Benchmark Research Honored With Industry Accolades
11. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... N.J., June 23 SyntheMed, Inc. (OTC Bulletin Board: ... commercialization of anti-adhesion products, announced today that the company ... Health Innovation Award in pediatrics. The company ... & Sullivan medical device analysts in recognition of the ...
... CHICAGO, June 23 Advanced Life Sciences Holdings, Inc. ... non-human primate study involving its novel, once-a-day, oral antibiotic ... achieved a 100% survival rate against an inhaled lethal ... study that received 16 mg/kg once-a-day (the human equivalent ...
... to Double 2009 Grant Awards to Nearly $4 Million ... The Lustgarten Foundation, the nation,s largest private supporter of pancreatic ... totaling $1.6 million awarded to six leading research centers for ... nation,s deadliest cancers. , , Lustgarten is expected ...
Cached Biology Technology:SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... weekend warriors: the simple act of exercise and not ... a new University of Florida study finds. People ... gaining strength or boosting cardiovascular fitness feel just as ... said Heather Hausenblas, a UF exercise psychologist. Her study ...
... sees the launch of Ensembl Plants a ... by the European Molecular Biology Laboratory,s European ... Spring Harbor Laboratory, USA. Ensembl Plants allows researchers ... genome-scale experiments in different plant species. By pinpointing ...
... disease and other diet related health problems received a 4 ... projects. The projects, taking place in universities and research institutes ... publicly-funded Research Councils and 15 companies. This means the research ... in our society but in a way that the food ...
Cached Biology News:UF study: Exercise improves body image for fit and unfit alike 2UF study: Exercise improves body image for fit and unfit alike 3New portal for plant genomics will support research into improved crops 2Public sector and industry unite to attack obesity and heart disease 2
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: